Citadel Advisors’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-1,204,700
Closed -$120M 10286
2019
Q3
$120M Buy
1,204,700
+876,600
+267% +$83.3M 0.06% 324
2019
Q2
$30.3M Sell
328,100
-1,432,100
-81% -$136M 0.01% 1061
2019
Q1
$166M Buy
1,760,200
+463,000
+36% +$40.5M 0.08% 191
2018
Q4
$83.1M Buy
1,297,200
+123,600
+11% +$9.12M 0.05% 392
2018
Q3
$105M Sell
1,173,600
-930,600
-44% -$82.2M 0.05% 396
2018
Q2
$167M Buy
2,104,200
+455,800
+28% +$37.8M 0.08% 202
2018
Q1
$147M Sell
1,648,400
-847,600
-34% -$81.4M 0.08% 200
2017
Q4
$260M Buy
2,496,000
+1,785,300
+251% +$201M 0.16% 96
2017
Q3
$104M Buy
710,700
+37,300
+6% +$5.08M 0.08% 245
2017
Q2
$87.5M Buy
673,400
+181,300
+37% +$22.2M 0.07% 276
2017
Q1
$61.2M Sell
492,100
-169,700
-26% -$20.3M 0.06% 356
2016
Q4
$76.6M Buy
661,800
+130,200
+24% +$14.5M 0.08% 233
2016
Q3
$55.6M Sell
531,600
-41,000
-7% -$4.44M 0.06% 341
2016
Q2
$56.5M Buy
572,600
+169,300
+42% +$17.5M 0.06% 296
2016
Q1
$40.4M Sell
403,300
-90,500
-18% -$9.32M 0.05% 381
2015
Q4
$59.1M Sell
493,800
-92,000
-16% -$10.6M 0.06% 328
2015
Q3
$63.4M Buy
585,800
+74,200
+15% +$9.21M 0.06% 335
2015
Q2
$59.2M Sell
511,600
-232,600
-31% -$26.6M 0.05% 423
2015
Q1
$85.8M Sell
744,200
-54,600
-7% -$6.52M 0.08% 270
2014
Q4
$89.4M Buy
798,800
+112,500
+16% +$11.9M 0.09% 231
2014
Q3
$65M Buy
686,300
+191,500
+39% +$17.3M 0.07% 317
2014
Q2
$42.5M Sell
494,800
-584,600
-54% -$44.5M 0.05% 456
2014
Q1
$75.3M Sell
1,079,400
-17,400
-2% -$1.38M 0.09% 237
2013
Q4
$92.7M Buy
1,096,800
+240,600
+28% +$19M 0.12% 167
2013
Q3
$65.9M Buy
856,200
+62,600
+8% +$4.39M 0.1% 212
2013
Q2
$46.4M Buy
+793,600
New +$47.8M 0.08% 281

Other funds holding CELG

Citadel Advisors's CELG Position: Q4 2019 in Review

Citadel Advisors sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 6,854,309 shares — an estimated $681M sold.

Citadel Advisors first reported a position in CELG in Q2 2013 and held it in 22 quarters. The position peaked at $681M in Q3 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Citadel Advisors reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Citadel Advisors sold 6,854,309 Celgene Corp shares in Q4 2019, an estimated $681M.
  • Citadel Advisors first reported a position in Celgene Corp in Q2 2013 and held it in 22 quarters.
  • Citadel Advisors's Celgene Corp position peaked at $681M in Q3 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.